BRIDGEBIO PHARMA INC (1BBIO.MI) Stock Price & Overview
BIT:1BBIO • US10806X1028
Current stock price
The current stock price of 1BBIO.MI is 64.23 EUR. Today 1BBIO.MI is up by 8.57%.
1BBIO.MI Key Statistics
- Market Cap
- 12.452B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.23
- Dividend Yield
- N/A
1BBIO.MI Stock Performance
1BBIO.MI Stock Chart
1BBIO.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1BBIO.MI.
1BBIO.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1BBIO.MI. 1BBIO.MI has a bad profitability rating. Also its financial health evaluation is rather negative.
1BBIO.MI Earnings
On February 24, 2026 1BBIO.MI reported an EPS of -1 and a revenue of 154.18M. The company missed EPS expectations (-32.11% surprise) and beat revenue expectations (2.94% surprise).
1BBIO.MI Forecast & Estimates
29 analysts have analysed 1BBIO.MI and the average price target is 84.5 EUR. This implies a price increase of 31.56% is expected in the next year compared to the current price of 64.23.
For the next year, analysts expect an EPS growth of 46.69% and a revenue growth 87.45% for 1BBIO.MI
1BBIO.MI Groups
Sector & Classification
1BBIO.MI Financial Highlights
Over the last trailing twelve months 1BBIO.MI reported a non-GAAP Earnings per Share(EPS) of -3.23. The EPS decreased by -22.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.45% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
1BBIO.MI Ownership
1BBIO.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.81 | 41.518B | ||
| ARGX | ARGENX SE | 28.75 | 41.431B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.62B | ||
| 2X1 | ABIVAX SA | N/A | 7.62B | ||
| ABVX | ABIVAX SA | N/A | 7.612B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| GLPG | GALAPAGOS NV | N/A | 1.605B | ||
| NANO | NANOBIOTIX | N/A | 1.361B | ||
| PHGN | PHARMING GROUP NV | 47.2 | 1.009B | ||
| PHARM | PHARMING GROUP NV | 46.97 | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 946.39M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M | ||
| IVA | INVENTIVA SA | N/A | 907.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1BBIO.MI
Company Profile
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 834 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Company Info
IPO: 2019-06-27
BRIDGEBIO PHARMA INC
3160 Porter Dr., Suite 250
Palo Alto CALIFORNIA US
Employees: 834
Phone: 13026587581
BRIDGEBIO PHARMA INC / 1BBIO.MI FAQ
Can you describe the business of BRIDGEBIO PHARMA INC?
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 834 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
What is the current price of 1BBIO stock?
The current stock price of 1BBIO.MI is 64.23 EUR. The price increased by 8.57% in the last trading session.
Does BRIDGEBIO PHARMA INC pay dividends?
1BBIO.MI does not pay a dividend.
How is the ChartMill rating for BRIDGEBIO PHARMA INC?
1BBIO.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for 1BBIO.MI stock?
29 analysts have analysed 1BBIO.MI and the average price target is 84.5 EUR. This implies a price increase of 31.56% is expected in the next year compared to the current price of 64.23.
Can you provide the PE ratio for 1BBIO stock?
BRIDGEBIO PHARMA INC (1BBIO.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.23).